Arcus Biosciences closes $107mm Series C round

14:40 EST 14 Nov 2017 | Elsevier Business Intelligence

Arcus Biosciences Inc. (cancer immunotherapies) raised $107mm through its Series C round. GV (formerly Google Ventures) led a...

Original Article: Arcus Biosciences closes $107mm Series C round


More From BioPortfolio on "Arcus Biosciences closes $107mm Series C round"

Quick Search


Relevant Topics

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...